A5102850314- Carcinogens and Genotoxicity Assessment
- Gastric Cancer Management and Outcomes
- Viral gastroenteritis research and epidemiology
- Viral Infections and Immunology Research
- Metabolism, Diabetes, and Cancer
- Genetic factors in colorectal cancer
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Gut microbiota and health
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Diabetes Treatment and Management
- Cancer Risks and Factors
Chinese Academy of Medical Sciences & Peking Union Medical College
2023-2025
Union Hospital
2021-2022
Huazhong University of Science and Technology
2021-2022
Chang Gung University
2007
The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy optimal dosage trastuzumab deruxtecan (T-DXd) in managing human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. sought to assess cost-effectiveness T-DXd both United States (US) Chinese healthcare systems. Markov models were developed evaluate overall cost, incremental ratio (ICER), quality-adjusted life years (QALYs), (LYs)...
Colorectal cancer is one of the tumors with highest morbidity and mortality rates in China world. Regorafenib a targeted drug for standard third-line treatment metastatic colorectal (mCRC). monotherapy has shown certain efficacy elderly population, but more robust evidence needed. The aim this study was to evaluate dosing characteristics, prognosis, safety regorafenib Chinese patients mCRC.